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If and how the heart regenerates after an injury event is highly debated. c-kit-expressing cardiac progenitor cells have been reported as the primary source for generation of new myocardium after injury. Here we generated two genetic approaches in mice to examine whether endogenous c-kit 1 cells contribute differentiated cardiomyocytes to the heart during development, with ageing or after injury in adulthood. A complementary DNA encoding either Cre recombinase or a tamoxifen-inducible MerCreMer chimaeric protein was targeted to the Kit locus in mice and then bred with reporter lines to permanently mark cell lineage. Endogenous c-kit 1 cells did produce new cardiomyocytes within the heart, although at a percentage of approximately 0.03 or less, and if a preponderance towards cellular fusion is considered, the percentage falls to below approximately 0.008. By contrast, c-kit 1 cells amply generated cardiac endothelial cells. Thus, endogenous c-kit 1 cells can generate cardiomyocytes within the heart, although probably at a functionally insignificant level.
The adult mammalian heart was originally proposed to be essentially incapable of renewal after injury or with ageing; although some recent studies have shown that the heart is capable of new cardiomyocyte formation with varying degrees of regenerative potential 1 . The concept that stem cells are the source for cardiomyocyte regeneration arose from initial observations in which bone-marrow-derived c-kit 1 haematopoietic stem cells (HSCs) showed restoration of the myocardium after infarction injury when given exogenously 2 . However, subsequent studies demonstrated that HSCs possessed essentially no ability to make cardiomyocytes, calling into question these earlier reports 3, 4 , at which time the field shifted to a focus on endogenous c-kit 1 cardiac progenitor cells (CPCs) residing within the myocardium 5 . Such cells isolated from the rat heart were reported to differentiate into cardiomyocytes, smooth muscle cells and endothelial cells, even after clonal derivation, and when injected into the infarct region they produced substantial new myocardium 6 . Mouse and human c-kit 1 CPCs were also isolated and marked, and after injection into an infarcted mouse heart, were shown to generate substantial levels of labelled cardiomyocytes, capillaries and fibroblasts 7 . More recently, resident c-kit 1 CPCs were reported to be both necessary and sufficient for complete repair and functional restoration of the myocardium after isoproterenol-induced cardiomyocyte killing, whereas bone-marrowderived c-kit 1 cells had no regenerative effect 8 . However, other studies with adult cardiac resident c-kit 1 cells have reported the opposite: that these cells do not possess the ability to generate cardiomyocytes in vivo 4, 9, 10 . To address ongoing controversy, we generated mice in which the Kit locus was used for lineage tracing analysis to examine if and how frequently c-kit 1 cells generate cardiomyocytes in vivo.
c-kit 1 contribution to the growing heart
The Kit locus was targeted with a cDNA encoding Cre recombinase fused to an internal ribosome entry sequence (IRES) to concurrently express enhanced green fluorescent protein (eGFP)-tagged with a nuclear localization signal (nls) (Fig. 1a ). These Kit 1/Cre mice were bred to LoxP sitedependent Rosa26-CAG-loxP-STOP-loxP-eGFP (R-GFP) reporter mice to irreversibly mark any cell that previously or currently expresses this Kit locus (Fig. 1a ). Four to twelve weeks after birth, the fidelity of the genetic system was assessed in comparison with known domains of c-kit protein expression, such as melanocytes of the skin, Leydig cells in the testis, interstitial cells of the intestine, lung and wide areas of the spleen, all of which showed eGFP cellular labelling ( Fig. 1b and Extended Data Fig. 1a ) [11] [12] [13] . In bone marrow, 83% of the c-kit-antibody-detected cells were eGFP 1 by standard fluorescence-activated cell sorting (FACS) analysis ( Fig. 1c ), while imaging cytometry analysis detected coincident eGFP 1 expression and c-kit immunoreactivity in 88% of the bone marrow cells and 76% of the non-myocyte fraction from the heart ( Fig. 1d, e ). To further verify the specificity of the Kit-Cre allele we examined realtime eGFPnls expression in the heart, ileum and skeletal muscle for co-expression of c-kit protein (antibody), which was always coincident (Fig. 1f , g and Extended Data Fig. 1b , c). In bone marrow, 94% of the eGFP 1 cells were Lin 1 , indicating a high degree of fidelity with the Kit-Cre allele (Extended Data Fig. 1d ). In the heart c-kit-antibody-positive mononuclear cells were predominantly eGFP 1 at 4 weeks of age using the Kit 1/Cre 3 R-GFP reporter strategy, whereas in testis recombination was only observed in Leydig cells, of which .80% were eGFP 1 (Extended Data Fig. 1e, f) . Thus, the specificity of the Kit-Cre allele appears identical with known regions of c-kit protein expression in vivo.
In an exhaustive search by histological methods across four hearts from Kit 1/Cre mice for current eGFPnls expression at 4 weeks of age, no eGFP 1 cardiomyocytes or endothelial cells were identified (only mononuclear CPC-like cells were observed), strongly suggesting that the Kit locus is not spontaneously activated in differentiated cell types of the heart (Fig. 1f ). However, in conjunction with the R-GFP reporter allele for ongoing c-kit lineage tracing, the myocardium showed many eGFP 1 differentiated cell types, although cardiomyocytes were very rare ( Fig. 1h , i). Even more rarely, areas suggestive of cardiomyocyte clonal expansion were identified ( Fig. 1i ). No eGFP 1 cells were observed in hearts of single R-GFP mice (data not shown). To more rigorously quantify the extent of cardiomyocyte recombination-based labelling, hearts were disassociated and eGFP 1 cells were directly counted ( Fig. 1j ), revealing a level of 0.027% myocytes from the c-kit lineage (Fig. 1k ). This low percentage was confirmed by PCR analysis for DNA recombination at the Rosa26 locus from purified cardiomyocytes versus spleen (Fig. 1l ).
c-kit 1 non-myocyte lineage analysis
Hearts of Kit 1/Cre 3 R-GFP mice at 4-12 weeks of age were further examined to identify the remaining eGFP 1 non-myocytes. Examples of eGFP labelling co-incident with fibroblasts (vimentin co-labelling), endothelial cells (CD31, CD34, von Willebrand factor (vWF)), immune cells (CD3, CD45) and, rarely, smooth muscle a-actin (a-SMA)-expressing cells, were identified, although the most prevalent co-localizations were with CD31-, CD45-or CD34-positive cells ( Fig. 2a-g) . Indeed, using a cocktail of antibodies for CD31, CD45, CD34 and CD3, versus sarcomeric a-actin, we were able to account for almost all eGFP 1 nonmyocytes in the hearts of adult Kit 1/Cre 3 R-GFP mice, either when analysed from histological sections or as dissociated individual cells (Extended Data Fig. 2a -c). FACS analysis showed that 18% and 77% of the total eGFP 1 non-myocytes in the heart were CD45 or CD31 positive, respectively ( Fig. 2h , i). Confocal microscopy analysis showed exact colocalization between eGFP 1 cells in the heart and CD31 protein expression, but not with NG2 staining for pericytes ( Fig. 2j ).
We also collected Kit 1/Cre 3 R-GFP mice at birth (postnatal day (P)0) to analyse the contributions of c-kit 1 cells to the heart during embryonic and fetal development (Extended Data Fig. 3a ). Control histological sections from the ileum and lung showed the expected distribution of c-kit 1 cells (Extended Data Fig. 3b ), and the heart also showed numerous eGFP 1 cells throughout (Extended Data Fig. 3c ). Immunohistochemical a-g, Representative immunofluorescent images of heart histological sections from Kit 1/Cre 3 R-GFP mice at 4 weeks of age stained with eGFP antibody (green), nuclei in blue and either CD31, vWF, CD34, CD3, CD45, vimentin or a-SMA in red. Arrows show cells with overlap in staining (n 5 3 hearts examined). h, i, FACS plot showing lineage markers of heart-isolated c-kitderived eGFP 1 cells for CD45 (h) and CD31 (i) (representative of n 5 6 for CD45 at 4 weeks of age, and n 5 3 for CD31 at 12 weeks of age). j, Representative immunofluorescent image from heart histological section of a Kit 1/Cre 3 R-GFP mouse at 4 weeks for eGFP fluorescence (green), CD31 antibody staining (blue) and NG2 antibody staining (red). Right panel shows composite with transmitted light (n 5 2 hearts analysed).
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analysis of the P0 heart with a sarcomeric cardiomyocyte marker showed that nearly all of the eGFP 1 cells were non-myocytes, although definable cardiomyocytes were clearly present at very low levels, including rare areas of cardiomyocyte clonal expansion (Extended Data Fig. 3d -g).
c-kit 1 lineage tracing in adult heart
To specifically address the question of new cardiomyocyte formation within the adult heart, we generated a mouse model in which the tamoxifen-inducible MerCreMer protein was targeted to the Kit locus (Kit 1/MCM ), followed by cross breeding with the R-GFP reporter line ( Fig. 3a) . To verify the fidelity of this system, Kit 1/MCM 3 R-GFP mice were given tamoxifen during postnatal maturation for approximately 4 weeks followed by collection of tissues with known sites of c-kit expression (Extended Data Fig. 4a ). Kit 1/MCM 3 R-GFP mice showed <70% overlap in recombination-dependent eGFP expression and endogenous c-kit protein in Leydig cells of the testis (Extended Data Fig. 4b ). Importantly, no eGFP 1 cells were observed in the absence of tamoxifen at any age examined or after myocardial infarction injury, demonstrating that the MerCreMer system does not 'leak' (Extended Data Fig. 4c ). Kit 1/MCM 3 R-GFP mice were also given tamoxifen from day 1 through 6 months of age for continuous labelling (Fig. 3b ), which produced eGFP expression in greater than 60% of bone marrow cells, but again no signal in the absence of tamoxifen ( Fig. 3c-e ). Histological analysis of the heart after 6 months of labelling showed rare examples of eGFP 1 adult cardiomyocytes and a relatively large number of nonmyocytes ( Fig. 3f, g ). Careful analysis of the non-myocyte fraction in these hearts showed fibroblasts (rarely), smooth muscle cells (rarely), endothelial cells and immune cells, with the majority again being CD31 1 (Extended Data Fig. 5a -g). Myocardial infarction injury also doubled the number of CD31 cells that were eGFP 1 in the adult heart with 8 weeks of prior tamoxifen labelling (Extended Data Fig. 5h ). We also conducted c-kit lineage labelling from 6-12 weeks of age, just after the postnatal developmental period (Fig. 3h ). Upon disassociation of these hearts we observed 0.0055% eGFP 1 adult cardiomyocytes ( Fig. 3i , j), confirmed as extremely low by PCR and quantitative PCR (qPCR) for Rosa26 locus recombination (Extended Data Fig. 6a -c).
Cardiac injury increases cellular turnover in the heart, hence we subjected Kit 1/MCM 3 R-GFP mice to myocardial infarction at 10 weeks of age during a 6-week tamoxifen-labelling protocol ( Fig. 3k and Extended Data Fig. 6d-f ). The percentage of eGFP 1 cardiomyocytes increased to . h-j, Tamoxifen treatment of Kit 1/MCM 3 R-GFP mice between 6-12 weeks of age followed by disassociation of cells from the hearts of these mice in h (white arrow in i shows rare cardiomyocyte) that is quantified in j (127,284 cardiomyocytes across two hearts, 7 were eGFP 1 , *P , 0.05 versus R-GFP). k-n, Tamoxifen treatment of Kit 1/MCM 3 R-GFP mice between 8 and 14 weeks of age with myocardial infarction (MI) on week 10 (n 5 3 mice analysed). l, Immunohistological heart section for desmin (red) and eGFP (green) with nuclei in blue (arrow shows a cardiomyocyte from the c-kit 1 lineage). m, n, Disassociated cardiomyocytes show rare but definitive myocyte labelling (white arrow), which was quantified in n (225,760 cardiomyocytes from 2 myocardial infarction-injured hearts, 37 were eGFP 1 , *P , 0.05 versus R-GFP). o, p, Tamoxifen treatment between 8 and 12 weeks of age with myocardial infarction injury occurring 3 days after tamoxifen cessation. p, Average number of eGFP 1 cardiomyocytes from histological sections taken across the entire heart (n 5 2 hearts, .50 sections each) *P , 0.05 versus R-GFP. All error bars represent s.e.m.
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0.016% within the heart, with more being localized to the infarct border zone ( Fig. 3l-n ). c-kit 1 lineage cells within the heart were also prelabelled by giving tamoxifen only before myocardial infarction injury, which again showed a very low percentage of eGFP 1 cardiomyocytes ( Fig. 3o, p) . Percentages of eGFP 1 cardiomyocytes in the heart during 4 weeks of isoproterenol infusion-induced injury were 0.007% (Extended Data Fig. 7a -c). These astonishingly low values of cardiomyocyte formation were independently verified using blinded heart histological sections from Kit 1/MCM 3 R-GFP mice sent to an outside academic laboratory (Extended Data Fig. 8a-c) . Finally, we also cultured total non-myocytes from the hearts of young adult Kit 1/Cre 3 R-GFP mice in the presence of dexamethasone as a means of pushing c-kit 1 cells with progenitor-like activity towards the cardiomyocyte lineage (Extended Data Fig. 9 ). The data show that eGFP 1 , Kit-Cre allele expressing cells are fully capable of inducing expression of the cardiac markers GATA4, a-actinin and troponin T, suggestive of partial differentiation towards the cardiomyocyte lineage (sarcomeres were not observed).
c-kit 1 cells fuse in the heart
Hearts from Kit 1/MCM 3 R-GFP mice showed the presence of cells from blood lineages (CD3, CD45, CD34), which are known to have fusigenic activity with resident parenchymal cells 3,14-18 . To examine fusion we used a genetic strategy that constitutively expresses a membrane-targeted fluorescent tdTomato protein from the Rosa26 locus. Upon Cre-mediated recombination, tdTomato fluorescence is lost and a membrane-targeted eGFP becomes expressed (abbreviated mT/mG for membrane-targeted tdTomato and eGFP, respectively) ( Fig. 4a ). If cells fuse, both signals would be present but a de novo cardiomyocyte from a c-kit 1 lineage cell would be only green. Experimentally, Kit 1/MCM 3 mT/mG mice were given tamoxifen for 2 weeks (8-10 weeks of age) then 3 days later myocardial infarctions, followed by collection at 1, 2 and 4 weeks thereafter ( Fig. 4b) . Control mice were collected before myocardial infarction but after tamoxifen (time 0). Percentages of total cardiomyocyte membrane-eGFP labelling, whether from fusion or not, were approximately 0.01% at all three time points after myocardial infarction (Fig. 4c ). Although some de novo cardiomyocytes were identified in the heart (eGFP only), the majority (80-88%) retained the membrane-tdTomato label indicating that these cells probably arose by fusion ( Fig. 4d-f ). Thus, c-kit 1 lineage cells can generate cardiomyocytes in the heart, although at <5-fold lower values than initially predicted.
Kit-Cre locus is not ectopically induced
One concern with the Kit allele-based lineage tracing approach is that if this locus ever becomes activated ectopically in a cardiomyocyte, it would be wrongly ascribed as having come from a c-kit 1 cell. It was previously shown that knockdown of the Kit gene in naturally occurring w and wv mutant mice results in defective progenitor cell activity in many tissues [19] [20] [21] [22] . Indeed, hearts from Kit w/wv mice showed a marked reduction in resident mononuclear c-kit 1 cells and progenitor activity 23 . Hence, Kit null mice should lack the ability to generate eGFP 1 cardiomyocytes in the heart if they indeed arise from c-kit 1 cells with progenitor-like activity, instead of having arisen from ectopic Kit allele induction in a rare population of differentiated cardiomyocytes.
Kit null mice were generated by placing the Kit-Cre allele over the Kit-MerCreMer allele. Although these mice die at birth, viable nulls at embryonic days 16.5 and 18.5 were identified and examined ( Fig. 4g-i) . 
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3 R-GFP and 1 Kit 1/Cre 3 mT/mG embryos across 56 histological sections spanning the heart (Fig. 4j, l) . However, hearts from two Kit MCM/Cre 3 R-GFP and one Kit MCM/Cre 3 mT/mG embryos (nulls) showed lower total eGFP 1 cells in the heart and no cardiomyocytes across 69 histological sections (Fig. 4i, k, m) . Importantly, Kit MCM/Cre embryos showed no c-kit protein expression confirming their null status (Fig. 4n ). Taken together, these data indicate that eGFP 1 cardiomyocytes that are lineage traced with the Kit-Cre allele are not due to inappropriate activation of the Kit gene for even a brief period of time in rare existing cardiomyocytes, but rather they either arose by transdifferentiation from c-kit 1 lineage precursor cells or by fusion.
Discussion
The original hypothesis that c-kit 1 cells have the ability to contribute to the cardiomyocyte compartment of the heart, as well as other cell types, is correct as determined by the lineage tracing technique used here 6 . Indeed, the observation that embryonic and postnatal labelling in the hearts of Kit 1/Cre 3 R-GFP mice shows definable regions with cardiomyocyte clonal expansion strongly suggests that these c-kit 1 cells can make cardiomyocytes in vivo. More importantly, loss of the Kit gene, which is known to compromise the progenitor and migration activity of c-kit 1 cells, completely prevented cardiomyocyte formation from c-kit 1 cells. However, throughout development, with ageing or with cardiac injury, the percentage of cardiomyocytes emerging from the c-kit 1 lineage was astonishingly low and hence highly unlikely to ever considerably affect cardiac function. The mT/mG detection system also supported the existence of de novo cardiomyocyte formation in the adult heart from the c-kit 1 lineage but at <5-fold lower levels than initially quantified owing to prevalent cellular fusion events. Exogenous c-kit 1 cells are currently being used to treat postmyocardial infarction heart failure patients, and early results have shown small, albeit significant, functional improvements in the heart 24 . However, our results suggest that the potential benefit of injecting c-kit 1 cells into the hearts of patients is unlikely attributable to new cardiomyocyte formation, hence caution is warranted until the mechanisms in play are better defined, or until we are able to considerably enhance the cardiogenic potential of these cells (see Supplementary Discussion) .
METHODS SUMMARY
The Kit allele was targeted in SV129 embryonic stem cells to express either Cre recombinase alone or a tamoxifen-inducible Cre recombinase referred to as MerCreMer. Hemizygous targeted mice were crossed with FVB.Cg-Gt(ROSA)26Sor tm1(CAG-lacZ,EGFP)Glh /J (previously modified by cross-breeding to B6(C3)-Tg(Pgk1-FLPo)10Sykr/J) or B6.129(Cg)-Gt(ROSA)26Sor tm4(ACTB-tdTomato,-EGFP)Luo /J. Tissues from these mice were subjected to histological analysis and immunohistochemistry at multiple ages and after select treatments. Antibodies used are shown in Supplementary Table 1 (see Methods for more detailed descriptions).
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS

Mice.
All experiments involving mice were approved by the Institutional Animal Care and Use Committee (IACUC) at Cincinnati Children's Hospital. No human subjects or human material was used. Targeted Kit-Cre-IRES-eGFPnls and Kit-MerCreMer mice were generated by standard gene targeting techniques. Homology arms upstream and downstream of the ATG start codon of the Kit gene in exon 1 were subcloned into a plasmid backbone containing Amp r and a diphtheria toxin (DTA) cassette through recombineering. A cDNA encoding either Cre-IRES-eGFPnls (from A. P. McMahon, UCLA) or MerCreMer, as well as an frt site-flanked neomycin selection cassette, were cloned in-frame with the Kit ATG start site. Embryonic stem (ES) cells were electroporated with linearized targeting vector. Targeted clones were identified by Southern blot and PCR. ES cell aggregation with 8-cell embryos was used to generate chimaeric mice with the Kit-Cre-IRES-eGFPnls construct 25 , whereas the Kit-MerCreMer mice were generated by blastocyst injection at the Howard Hughes Medical Institute (HHMI) gene-targeting core facility (by C. Guo at HHMI, who also generated the Kit-MerCreMer targeting vector and targeted ES cells). Germline transmitting male chimaeras were crossed with Rosa26-Flpe females (B6.129S4-Gt(ROSA)26Sor tm1(FLP1)Dym /RainJ) to delete the neomycin cassette and verified offspring were further backcrossed to C57Bl/6J for five generations. Reporter mice FVB.Cg-Gt(ROSA)26Sor tm1(CAG-lacZ,EGFP)Glh /J (previously modified by cross-breeding to B6(C3)-Tg(Pgk1-FLPo)10Sykr/J) and B6.129(Cg)-Gt(ROSA) 26Sor tm4(ACTB-tdTomato,-EGFP)Luo /J were purchased from the Jackson Laboratories. Kit null mice were generated by breeding male Kit 1/Cre with female Kit 1/MCM 3 R-GFP mice, of which 1:8 embryos are predicted to be Kit MCM/Cre 3 R-GFP (nulls, with the reporter). Littermates that were Kit 1/Cre 3 R-GFP were controls to show the full extent of eGFP 1 cardiomyocytes that are possible in the heart. Because Kit null mice were not identified at birth in multiple litters, we collected mice from this cross at E16. 5 21 . The duration of treatment is indicated within each experiment. Myocardial infarction was induced in mice via permanent surgical ligation of the left coronary artery 26 . In brief, mice (both sexes) were anaesthetized using isoflurane and a left lateral thoracotomy was performed. The left coronary artery was identified and ligated just below the left atrium. After closing the thoracotomy and expelling residual air, the mice were allowed to recover. Two-dimensional M-mode echocardiography was performed on mice anaesthetized with 2% isoflurane, using a Hewlett Packard SONOS 5500 with a 15-MHz transducer. An average of three measurements was taken for each mouse. Group sizes were determined from past experience and based on statistical power calculations, and the number of mice is given in the figure or figure legends. Isoproterenol treatment was given via osmotic minipumps (Alzet) at 60 mg per kg per day (in 1 mM ascorbic acid) for 4 weeks. Mice were either killed by CO 2 asphyxiation followed by cervical dislocation or by deep isoflurane sedation with cervical dislocation followed by excision of the heart. Isolated organs were fixed in 4% paraformaldehyde overnight, then processed for paraffin embedding or fixed for 3 h and immersed in PBS containing 30% sucrose overnight before embedding in OCT (Tissue-Tek) for cryo-sectioning. Cell isolation. We isolated bone marrow cells by flushing femurs and tibiae with Hanks Balanced Salt Solution (HBSS). In brief, bone marrow was flushed using a 25-gauge needle attached to a syringe containing 10 ml ice-cold HBSS supplemented with 2% fetal calf serum (FCS). Cells were spun at 400g for 10 min at 4 uC and pellets were re-suspended in 2% FCS/HBSS. After isolation, cells were kept on ice and further processed for flow cytometry or DNA extraction. Adult cardiomyocytes were isolated by removal of beating hearts from anaesthetized mice and cannulated for retrograde perfusion with modified Tyrode solution (NaCl 120 mM, KCl 14.7 mM, KH 2 PO 4 0.6 mM, Na 2 HPO 4 0.6 mM, MgSO 4 1.2 mM, HEPES 10 mM, NaHCO 3 4.6 mM, taurine 30 mM, glucose 5.5 mM, butanedione monoxime (BDM) 10 mM, pH 7.40) supplemented with Liberase TH (Roche) 27 . After perfusion, hearts were disassociated into individual cardiomyocytes, calcium was gradually added back and cells were plated on laminin-coated cover slips in modified Tyrode solution supplemented with 1 mg ml 21 BDM and immediately counted for eGFP 1 cardiomyocytes. After counting, cells were imaged with a Nikon Eclipse TE300 inverted fluorescence microscope. Non-cardiomyocytes from the heart were isolated by retrograde perfusion as described previously 28 . In brief, hearts were perfused with a digestion buffer (NaCl 126 mM, KCl 4.4 mM, MgCl 2 5 mM, Na pyruvate 5 mM, NaH 2 PO 4 5 mM, creatine 5 mM, HEPES 5 mM, glucose 22 mM, taurine 20 mM) containing 15 mM CaCl 2 , collagenase type 2 (Worthington, 274 U ml 21 ) and Protease XIV (Sigma-Aldrich, 0.57 U ml 21 ). Cardiomyocytes were eliminated by two serial centrifugations at 10g for 5 min at 4 uC and the non-cardiomyocyte cell fraction was collected after a final centrifugation at 500g for 10 min at 4 uC. Flow cytometry. Flow cytometry was performed on bone marrow and non-myocyte heart fractions using a BD FACSCanto II running FACSDiva software with the following configuration: 405-nm laser for Alexa 405, 633 nm for APC (allophycocyanin) and 488 nm for GFP. Voltages were determined using single-stain and fluorescence minus one (FMO) controls. Analysis was performed using FlowJo vX. Haematopoietic lineage committed bone marrow cells were identified and negatively gated using a panel of mouse antibodies (CD3e, CD11b, CD45R/B220, Ly6G and Ly-6C and TER-119; collectively Lin 2 ). c-kit 1 cells were identified by antibody labelling and then plotted for endogenous eGFP fluorescence. Alternatively, all bone marrow cells were labelled with c-kit antibody and then plotted for both c-kit positivity and endogenous eGFP fluorescence. Non-myocytes from the heart were first gated for eGFP fluorescence and plotted for CD45 or CD31 positivity using antibodies conjugated to APC for fluorescence intensity separation. Summary of antibodies used is given in Supplementary Table 1 .
Multispectral-imaging flow cytometry. Quantitative real-time c-kit and eGFP expression in bone marrow and non-cardiomyocyte cells from the hearts of Kit 1/Cre 3 R-GFP mice was analysed by ImageStreamX (Amnis), a multispectral flow cytometer combining standard microscopy with flow cytometry. We used the integrated software INSPIRE to run the ImageStreamX. For each experiment, cells were fixed and stained for c-kit antibody reactivity and suspended in 100 ml buffer (cold HBSS with 2% horse serum). Before running the samples, the ImageStreamX was calibrated using SpeedBeads (Amnis). Samples were acquired for unlabelled, single-colour fluorescence controls, then the experimental samples. At least 10,000 experimental cells and 2,000 control cells were acquired for each sample. Images were analysed using IDEAS image-analysis software (Amnis). Summary of antibodies used is given in Supplementary Table 1 . Immunohistochemistry. Please refer to Supplementary Table 1 for all antibody information and dilutions. For paraffin sections, isolated organs were fixed overnight in freshly diluted 4% paraformaldehyde, dehydrated and sectioned at 5 mm. Following citrate antigen retrieval (BioGenex), the sections were blocked for 1 h at room temperature in a blocking solution (PBS with 0.1% cold water fish skin gelatin, 1% bovine serum albumin, 0.1% Tween-20 and 0.05% NaN 3 ), which was also used to dilute antibodies. For cryosections, isolated organs were fixed for 3 h in freshly diluted 4% paraformaldehyde at 4 uC, rinsed with PBS and cryoprotected in 30% sucrose/PBS overnight before embedding in OCT (Tissue-Tek) and 10-mm cryosections were collected. Cryosections were blocked for 30 min at room temperature in a blocking solution (PBS with 5% goat serum, 2% bovine serum albumin, 0.1% Triton X-100), which was also used to dilute antibodies. Primary antibodies were incubated overnight at 4 uC, secondary antibodies for 2 h at room temperature, washes were performed in PBS. Cryosections were used to visualize native eGFP or tdTomato fluorescence from the different reporters or from the IRES-eGFP cassette built into the Kit-Cre allele. 4',6-diamidino-2-phenylindole (DAPI) was used to stain nuclei (usually in blue). Images were acquired on an inverted Nikon A1R confocal microscope using NIS Elements AR 4.13. Some images were further processed in Photoshop or Image J to increase brightness/contrast of individual channels before generating a pseudo-coloured overlay. Genomic PCR and qPCR. Genomic DNA was prepared from mouse tissues or isolated mouse cardiomyocytes using the DNeasy Blood & Tissue Kit (Qiagen, 69504) per manufacturer's instructions. In brief, cells or tissues were snap-frozen at time of collection then lysed by incubation with proteinase K for 3 h at 56 uC, followed by spin column purification and elution. Samples were treated with RNase A to remove contaminating RNA. PCR was performed to detect recombined and non-recombined Rosa26 reporter alleles using primers 59-tctgcttcactctccccatc (forward, against the CAG promoter/enhancer), 59-gatcagcagcctctgttccaca (forward, against the PGKNeo cassette) and 59-cgctgaacttgtggccgtttac (reverse, against eGFP). PCR conditions were 96 uC for 2 min to separate strands, followed by 34 cycles of amplification (96 uC for 30 s, 56 uC for 30 s, 72 uC for 30 s) and a 5-min elongation step at 72 uC. PCR products were visualized on an ethidium bromide-stained agarose gel using a UV molecular imager (Bio-Rad). To quantify levels of recombined and non-recombined Rosa26 alleles in genomic DNA, qPCR was performed using SYBR Green with the same primers used for PCR above (Applied Biosystems), and detection with a Bio-Rad CFx96 thermocycler. Simultaneous reactions using the primers above were performed to detect recombined versus non-recombined alleles. Western blots. Western blotting was performed essentially as described previously 29 . E16.5 embryos were homogenized in RIPA buffer containing protease inhibitor cocktail (Roche) with a dounce homogenizer. Forty micrograms of protein per RESEARCH ARTICLE sample were resolved on 10% SDS-PAGE gels, transferred onto PVDF membranes, immunoblotted with antibodies for c-kit (R&D Systems AF1356) and GAPDH (Fitzgerald 10R-G109a), and then incubated with the appropriate alkaline phosphate-linked secondary antibodies. The PVDF membranes were visualized by enhanced chemifluorescence (Amersham). In vitro cardiomyocyte differentiation. The non-cardiomyocyte cell fraction was isolated from a 3-month-old Kit 1/Cre 3 R-GFP mouse. Cells were plated at a density of 40,000 cells per well on gelatin-coated 6-well tissue culture dishes in DMEM media containing 10% FCS, antibiotics and non-essential amino acids. After 2 days, the cells were washed and treated with 10 nM dexamethasone in DMEM containing 10% FCS to induce differentiation 6 . The media was refreshed every 3 days. After 1 week the cells were fixed with 4% paraformaldehyde and subjected to immunohistochemistry for vimentin, a-actinin, troponin T and GATA4 (antibodies listed in Supplementary Table 1 ). The cells were then imaged on an inverted Nikon A1R confocal microscope. Statistics. For studies involving induction of myocardial infarction, group sizes were determined on the basis of previously observed postoperative mortality rates for this procedure. No experimental animals were excluded in any of the analyses. Blinding and randomization were not performed with the exception of the experiments in Extended Data Fig. 8 , which were done by two observers blinded to the sample identity. For flow cytometry experiments and direct counting of cardiomyocytes in histological sections or dissociated cardiomyocytes in dishes, two-group comparisons were performed using Student's two-tailed t-test, with P , 0.05 considered statistically significant. All error bars throughout the figures are s.e.m. and all represented data are averages. 
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Extended Data Figure 2 | Identification of non-myocytes from the hearts of Kit 1/Cre 3 R-GFP mice. Kit 1/Cre 3 R-GFP mice were collected at 6 weeks of age (constitutive lineage labelling the entire time), although myocardial infarction was performed at week 4 to induce greater vascular remodelling and potentially more c-kit lineage recruitment over the next 2 weeks. a, Hearts were then collected at week 6 and subjected to immunohistochemistry with a pool of antibodies for CD31, CD34, CD45 and CD3 in red, whereas the green channel was for eGFP expression from the recombined R-GFP reporter allele due to Kit-Cre lineage expression. The white arrowheads show endothelial cells that are not contiguous with the underlying network, although most of the endothelial cells are from the c-kit lineage when the red and green channels are compared. The white arrow shows a cardiomyocyte that lacks red staining, whereas the yellow arrows show two areas with relatively large cells that are eGFP 1 and could be mistaken for a cardiomyocyte, although they are also positive for the non-myocyte marker panel of antibodies (n 5 2 mice). b, c, Spread of cells isolated from hearts of 8-week-old Kit 1/Cre 3 R-GFP mice at baseline that were subjected to immunocytochemistry for the indicated markers (n 53 hearts). The large white arrow in panel b shows an eGFP 1 (green) cardiomyocyte that also co-stains with sarcomeric a-actin (red). The smaller arrows show eGFP 1 non-myocytes, which in panel c, were subject to staining with a cocktail of antibodies again for CD31, CD34, CD45 and CD3 (all in red). This analysis identifies nearly all of the non-myocytes in these cell spreads. The very last image in panel c shows a fourth channel with higher gain so that the underlying cardiomyocytes (CMs) autofluoresce (in white) to show the mixed nature of the spread cells. Blue staining depicts nuclei. The cardiomyocyte that is shown has clear striations in the eGFP staining pattern, whereas the two non-myocytes do not show striated eGFP and also lack sarcomeric a-actin staining. f, eGFP expression alone in green (left) with nuclei in blue or eGFP with sarcomeric a-actin co-staining (red) from heart sections at P0 of Kit 1/Cre 3 R-GFP mice. All eGFP 1 cells shown lack striations and are non-myocytes although the two cells in the centre sit directly on top of cardiomyocytes and could be easily misinterpreted. Great care is needed in scoring myocytes in the P0 heart because they are small and often the same size as eGFP 1 non-myocytes. g, eGFP expression (green) with nuclei in blue and cardiomyocytes identified in red with sarcomeric a-actin antibody from heart histological sections at P0 of Kit 1/Cre 3 R-GFP mice. Here the data show c-kit-lineage-derived cardiomyocytes that appear in a loose cluster (arrows), presumably from a clonal expansion event earlier in development.
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Extended Data Figure 4 | Additional examination of the Kit-MerCreMer knock-in allele and its potential leakiness in the absence of tamoxifen. a, Histological analysis of eGFP fluorescent cells from the indicated tissues of Kit 1/MCM 3 R-GFP mice that were given tamoxifen from 2 to 28 days of age and then collected at day 28. Nuclei are shown in blue and green shows eGFP 1 cells in the expected patterns for known regions of c-kit protein expression, such as the distinct pattern of melanocytes in the skin and widespread expression in the spleen and lungs. b, Representative immunohistochemical analysis in the testis of Kit 1/MCM 3 R-GFP mice for endogenous c-kit expression (red) versus cells that underwent recombination when tamoxifen was given by intraperitoneal injection (2 mg) for five consecutive days (green) (n 5 2 mice). The data show that most of the cells currently expressing c-kit protein in testis (only Leydig cells react, red surface staining) are also eGFP 1 (intracellular), indicating that recombination only occurs in c-kit-expressing cells, and in the majority of them. c, Representative histological heart sections from Kit 1/MCM 3 R-GFP mice that were placed on tamoxifen-laden food or vehicle food (n 5 6 mice per treatment) beginning at 4 weeks of age and then subjected to myocardial infarction injury 4 weeks later, followed by collection 4 weeks after that. In the presence of tamoxifen, histological sections through the myocardial infarction border zone of the heart show widespread eGFP 1 cells (green) from the c-kit lineage (left panel), whereas in the absence of tamoxifen no eGFP 1 cells are observed (right panel), indicating the Kit-MerCreMer allele does not leak at baseline or after myocardial infarction injury.
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